123 related articles for article (PubMed ID: 7879215)
1. OKT3-induced cytokine-release syndrome: occurrence beyond the second dose and association with rejection severity.
Vasquez EM; Fabrega AJ; Pollak R
Transplant Proc; 1995 Feb; 27(1):873-4. PubMed ID: 7879215
[No Abstract] [Full Text] [Related]
2. OKT3-induced cytokine-release syndrome: renal effects (cytokine nephropathy).
First MR; Schroeder TJ; Hariharan S
Transplant Proc; 1993 Apr; 25(2 Suppl 1):25-6. PubMed ID: 8465417
[No Abstract] [Full Text] [Related]
3. Treatment of steroid resistant rejection following renal transplantation: benefits and risks of OKT3 therapy.
Kehinde EO; Feehally J; Scriven SD; Veitch PS; Bell PR
Transplant Proc; 1996 Jun; 28(3):1449-50. PubMed ID: 8658735
[No Abstract] [Full Text] [Related]
4. Comparison of adjusted-dose vs standard-dose OKT3 therapy of acute rejection in pediatric kidney transplant recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1993 Aug; 25(4):2574. PubMed ID: 8356675
[No Abstract] [Full Text] [Related]
5. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
6. Adverse effects of OKT3 therapy: increased risk with impaired renal function.
Kehinde EO; Scriven SD; Feehally J; Veitch PS; Varty K; Bell PR
Transplant Proc; 1994 Aug; 26(4):1945-7. PubMed ID: 8066629
[No Abstract] [Full Text] [Related]
7. Incidence and outcome of OKT3 treatment for early steroid-resistant rejection following hepatic transplantation.
Lange D; Bechstein WO; Blumhardt G; Lemmens P; Schattenfroh N; Neuhaus P
Transplant Proc; 1993 Apr; 25(2):1870-1. PubMed ID: 8470207
[No Abstract] [Full Text] [Related]
8. Pentoxifylline reduces the first-dose reactions following OKT3.
Vincenti FG; Vasconcelos M; Birnbaum JL; Tomlanovich SJ; Amend WJ; Melzer JS; Snyder JP
Transplant Proc; 1993 Apr; 25(2 Suppl 1):57-9. PubMed ID: 8465428
[No Abstract] [Full Text] [Related]
9. Consequences of anti-OKT3 antibody development: OKT3 reuse and long-term graft survival.
Shield CF
Transplant Proc; 1993 Apr; 25(2 Suppl 1):81-2. PubMed ID: 8465434
[No Abstract] [Full Text] [Related]
10. Prevention of the OKT3 first-dose syndrome by reduced initial dose followed by adjusted doses based on CD3 T-lymphocyte counts in pediatric renal graft recipients.
Piatosa B; Grenda R; Prokurat S
Transplant Proc; 1996 Dec; 28(6):3466-7. PubMed ID: 8962349
[No Abstract] [Full Text] [Related]
11. Clinical and renal histologic predictors of long-term outcome after OKT3 therapy for steroid-resistant rejection.
Wiener Y; Nakhleh RE; Kupin WL; Lee M; Escobar FS; Venkat KK; Mozes MF
Transplant Proc; 1995 Feb; 27(1):1014-5. PubMed ID: 7878781
[No Abstract] [Full Text] [Related]
12. Delayed use of OKT3 for severe acute tubular necrosis in renal transplantation.
VanderWerf BA
Transplant Proc; 1996 Aug; 28(4):2115-6. PubMed ID: 8769172
[No Abstract] [Full Text] [Related]
13. Randomized prospective study comparing OKT3 and antithymocyte globulins for treatment of the first acute cellular rejection of kidney allografts.
Alamartine E; Bellakoul R; Berthoux F
Transplant Proc; 1994 Feb; 26(1):273-4. PubMed ID: 8108975
[No Abstract] [Full Text] [Related]
14. OKT3 treatment for steroid-resistant acute rejection in kidney transplantation.
Sevmis S; Emiroglu R; Karakayali F; Yagmurdur MC; Dalgic A; Moray G; Haberal M
Transplant Proc; 2005 Sep; 37(7):3016-8. PubMed ID: 16213290
[TBL] [Abstract][Full Text] [Related]
15. Treatment of cytomegalovirus infections with gancyclovir during OKT3 administration.
Haberal M; Velidedoğlu E; Arslan G; Bilgin N; Büyükpamukçu N; Karamehmetoğlu M
Transplant Proc; 1995 Oct; 27(5):2707. PubMed ID: 7482883
[No Abstract] [Full Text] [Related]
16. Proliferation rate of cells in the interstitial infiltrate in acute kidney allograft rejection.
Olsen S; Hansen HE
Transplant Proc; 1996 Feb; 28(1):502-3. PubMed ID: 8644329
[No Abstract] [Full Text] [Related]
17. Role of protocol biopsies in the treatment of refractory renal allograft rejection with FK 506.
Woodle ES; Thistlethwaite JR; Haas M; Josephson MA; Newell KA; Bruce DS; Millis JM; Piper JB; Charette JI
Transplant Proc; 1996 Apr; 28(2):998-9. PubMed ID: 8623495
[No Abstract] [Full Text] [Related]
18. Effect of oral pentoxyfylline on the OKT3-induced cytokine-release syndrome among renal allograft recipients.
Vasquez EM; Pollak R
Clin Transplant; 1996 Jun; 10(3):294-7. PubMed ID: 8826669
[TBL] [Abstract][Full Text] [Related]
19. Reduction of the initial febrile response to OKT3 with indomethacin.
First MR; Schroeder TJ; Hariharan S; Weiskittel P
Transplant Proc; 1993 Apr; 25(2 Suppl 1):52-4. PubMed ID: 8465426
[No Abstract] [Full Text] [Related]
20. Comparison between three different antilymphocyte induction protocols in renal transplant recipients with delayed graft function.
Sumrani N; Hong JH; DiBenedetto A; Clayton R; Miles AM; Markell MS; Distant DA; Fleishhacker J; Sommer BG
Transplant Proc; 1996 Feb; 28(1):400-1. PubMed ID: 8644289
[No Abstract] [Full Text] [Related]
[Next] [New Search]
